FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							

0.5

Estimated average burden hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Eychange Act of 1934

				i iicu ļ				Investment				JJ4						
1. Name and Address of Reporting Person* Raskin Gregory S					2. Issuer Name and Ticker or Trading Symbol Y-mAbs Therapeutics, Inc. [YMAB]								5. Relationship of Reporting Person(s) to Issue (Check all applicable)					
													X	Director			10% Ov	ner
(Last)	`	(First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 06/12/2019								Officer (give title below)		Other (sp below)		pecify
		-		$_{ov}$														
CANCER CENTER 1275 YORK AVENUE, BOX 524					4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)													X	Form fil	ed by One	Repo	rting Persor	ı
NEW YO	ORK N	Y	10065											Form fil Person	ed by More	e than	One Repor	ting
(City)	(S	tate)	(Zip)															
		Tal	ole I - Non	-Derivat	ive S	ecuritie	s Ac	quired, D	ispo	osed of	f, or Be	neficia	lly C	Owned				
Date			2. Transact Date (Month/Day		2A. Deemed Execution Date, if any (Month/Day/Yea		, Transaction Dispose Code (Instr. 5)		Disposed	es Acquire Of (D) (Ins	ed (A) or tr. 3, 4 and	4 and Securit Benefic Owned		s lly ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
							Code	, ,	Amount	(A) oi (D)	Price		Reported Transacti (Instr. 3 a	tion(s)			(Instr. 4)	
			Table II - [)					uired, Dis					/ Ov	vned			,	
Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\)	Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Do	Price of erivative ecurity istr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
				Cod	e V	(A)	(D)	Date Exercisable	Ex _l	piration ate	Title	Amount or Number of Shares						
Non- Employee Stock	¢21.45	06/12/2019				16,000		07/12/2010(2) 06/	2/12/2020	Common	16.000		\$ 0	16.000	,	D	

Explanation of Responses:

Option (right to

buy)(1)

\$21.45

- 1. Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. The Reporting Person has entered into a contract with Memorial Sloan Kettering Cancer Center pursuant to which the Reporting Person will contribute to Memorial Sloan Kettering Cancer Center his earnings from the interests described herein.
- 2. The stock options vest in equal monthly installments during the first year following the date of grant, subject to the Reporting Person's continued service on the board of directors of Y-mAbs Therapeutics, Inc., and are exercisable immediately upon vesting

07/12/2019⁽²⁾ 06/12/2029

/s/ Gregory S. Raskin

Stock

06/14/2019

16,000

D

** Signature of Reporting Person

16,000

\$0

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

06/12/2019

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

16,000